Supernus Pharmaceuticals
About Supernus
Supernus, Inc. is a leading, recognized biopharmaceutical company focused on the development and commercialization of treatments for patients with central nervous system (CNS) disorders. The company’s portfolio of approved commercial products is designed to assist patients living with conditions such as opioid use disorder (OUD), attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease (PD)—specifically addressing motor fluctuations (such as "off" episodes) and motor impairment associated with the disease or its treatment (including levodopa-induced dyskinesia). Leveraging our robust commercial capabilities and scientific expertise, we remain committed to innovation, advancing a promising pipeline of novel investigational products aimed at delivering effective therapeutic outcomes for individuals with CNS disorders.
- Founded
- 2005
- CEO
- Mr. Jack A. Khattar
- Employees
- 778
- Headquarters
- Rockville, Maryland, United States of America
- Fiscal year end
- 12-31
- Website
- supernus.com
Company profile
- Exchange
- US
- Symbol
- SUPN
- Market-cap rank
- #2636
- Listing date
- 1970-01-01
- Market cap
- 5.94B
- Float cap
- 5.78B
- Shares out
- 207.72M
- Float shares
- 201.93M
Sectors & themes
Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.
Supernus Pharmaceuticals discussion 0 comments